相关实验视频

Updated: Jan 6, 2026

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

Published on: June 19, 2025

孔合金矿的混合相状态中的磁化分布

Y Murakami¹, J H Yoo, D Shindo

¹Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan. murakami@tagen.tohoku.ac.jp

|June 27, 2003

概括

矿中的巨大磁阻 (CMR) 与它们复杂的磁性微观结构有关. 应用磁场会改变这种微妙的结构,使导电路成为可能,并导致CMR材料中观察到的异常电阻降低.

科学领域:

凝聚物质物理学凝聚物质物理学
材料科学材料科学材料科学
磁力学磁力学是一种

背景情况:

穿孔合的矿中的巨大磁阻 (CMR) 是一种显著的现象,其特点是在应用磁场下,电阻率大幅下降.
驱动CMR的精确机制仍然不完全理解,相隔状态,涉及共存的磁性和非磁性相,被认为是至关重要的.
这种混合相状态内的详细的磁性微观结构是影响CMR的关键未知因素.

研究的目的:

为了研究磁性微观结构和铁磁域进化在混合相状态的La(1-x) Sr(x) MnO3 (x = 0.54, 0.56).
为了阐明磁性微观结构和洞 doped 矿中巨大的磁阻效应之间的关系.

主要方法:

利用电子显微镜检查磁性微观结构.
研究了La(1-x) Sr(x) MnO3样本混合相状态中的铁磁域的发展.

主要成果:

观察到,在没有磁场的情况下,磁流被限制在铁磁区域内,这表明分离的铁磁领域之间的相互作用是最小的.
证明铁磁域开始与只有微小的温度波动合并.
在这些材料的混合相状态中确定了一个微妙的磁性微观结构.

结论:

孔合矿中混合相状态的微妙磁性微观结构被认为是导致巨大的磁阻效应的关键因素.
磁场的应用被证明可以促进铁磁域之间形成显著的导电路径,从而导致CMR.

更多相关视频

Cancer Vaccines

Cancer Vaccines

Development of Immunocompetence

Development of Immunocompetence

相关概念视频

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Vaccinations

Vaccinations

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...